McKinsey & Company partner Mekala Krishnan, the opening keynote speaker, set the bar high with a data-driven and solutions-oriented presentation and question-and-answer session.

McKinsey & Company partner Mekala Krishnan, the opening keynote speaker, set the bar high with a data-driven and solutions-oriented presentation and question-and-answer session.
McKinsey & Company partner Mekala Krishnan, the opening keynote speaker, set the bar high with a data-driven and solutions-oriented presentation and question-and-answer session.
McKinsey & Company partner Mekala Krishnan, the opening keynote speaker, set the bar high with a data-driven and solutions-oriented presentation and question-and-answer session.
McKinsey & Company partner Mekala Krishnan, the opening keynote speaker, set the bar high with a data-driven and solutions-oriented presentation and question-and-answer session.
Winograd leads UMSL’s Addiction Science team, which has been playing a central role in efforts to combat the overdose crisis in Missouri.
Winograd leads UMSL’s Addiction Science team, which has been playing a central role in efforts to combat the overdose crisis in Missouri.
Winograd leads UMSL’s Addiction Science team, which has been playing a central role in efforts to combat the overdose crisis in Missouri.
It is the highest rank in the University of Missouri System and recognizes faculty members for exceptional contributions to research, education and service.
It is the highest rank in the University of Missouri System and recognizes faculty members for exceptional contributions to research, education and service.
It is the highest rank in the University of Missouri System and recognizes faculty members for exceptional contributions to research, education and service.
APIIC and its partners have been awarded $14 million in federal funding to lead the development and domestic production of three critical APIs used in the treatment of asthma, diabetes and anxiety disorders.
APIIC and its partners have been awarded $14 million in federal funding to lead the development and domestic production of three critical APIs used in the treatment of asthma, diabetes and anxiety disorders.
APIIC and its partners have been awarded $14 million in federal funding to lead the development and domestic production of three critical APIs used in the treatment of asthma, diabetes and anxiety disorders.